Share Prices & Company Research

Stockbroking

Hikma Pharmaceuticals

Current Price 1954.00p Bid 1954.00p Ask 1954.50p Change -0.08%
Last Updated: 20/01/2020 17:55. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

Hikma Pharmaceuticals plc principal activities are the development, manufacture, and marketing of a broad range of branded and non-branded generic pharmaceuticals products across the US, the Middle East and North Africa (MENA) and Europe. Hikma is also a leading licensing partner in MENA.

Financial Highlights Year Ended 31/12/2018

Turnover
£2,070.00m
Operating Profit
£371.00m
Dividend Yield
1.57
Dividend Per Share
38.00
Dividend Cover
2.93
P/E Ratio
16.71

Key Personnel

Sigurdur Oli Olafsson
Chief Executive Officer
Said Samih Darwazah
Executive Chairman
Mazen Samih Darwazah
Executive Vice Chairman
Mary Regina Henderson
Non-Executive Director
Dr Pamela Josephine Kirby
Non-Executive Director
Robert Mark Pickering
Non-Executive Director
Cynthia Louise Schwalm
Non-Executive Director
Dr Jochen Gann
Non-Executive Director
John Julius Castellani
Non-Executive Director
Patrick Noel Butler
Non-Executive Director
Ali Mohammed Al-Husry
Non-Executive Director

Stock Details

EPIC
HIK
ISIN
GB00B0LCW083
Shares in Issue
242,319,174
Market cap
£4,738.55m

Analyst Views (7)

Strong Buy
 
28.57%
Buy
 
0.00%
Hold
 
42.86%
Sell
 
28.57%
Strong Sell
 
0.00%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
1954.00p
Bid Price
1954.00p
Ask Price
1954.50p
Volume
90037
Change Today
-1.50p
% Change Today
-0.08%
Open
1961.00p
Previous Close
1954.00p
Intraday High
1967.00p
Intraday Low
1936.50p
52 Week High
2212.00p
52 Week Low
1491.50p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

Hikma Pharmaceuticals Intra-day Chart

Hikma Pharmaceuticals News

News in this section is provided by AJ Bell

FTSE drifts on Pharma weakness and poor results 16 Jan 2020 | 16:45 FTSE drifts on Pharma weakness and poor results 16 Jan 2020 | 16:42 FTSE drifts on Pharma weakness and poor results 16 Jan 2020 | 16:40 Hikma Pharmaceuticals inks licensing, distribution agreement with Chiesi Farmaceutici 13 Jan 2020 | 09:09 UK stocks open 0.4% higher as Pennon surges on Viridor bid reports 13 Jan 2020 | 08:58 Hikma Pharmaceuticals teams up with Arecor to develop 'ready-to-use' injectable medicine in US 09 Jan 2020 | 08:24 Broker Forecast - JP Morgan Cazenove issues a broker note on Hikma Pharmaceuticals PLC 06 Jan 2020 | 10:40 Hikma Pharmaceuticals, Civica to ship heparin, other shortage drugs in US 10 Dec 2019 | 13:13 Broker Forecast - JP Morgan Cazenove issues a broker note on Hikma Pharmaceuticals PLC 03 Dec 2019 | 10:10 Hikma submits new clinical data for Advair generic drug to address questions raised by FDA 27 Nov 2019 | 09:07 Hikma Pharmaceuticals says revenue from generics business to be at top end of range 07 Nov 2019 | 07:16 Hikma Pharmaceuticals launches pre-filled syringes in US 17 Sep 2019 | 09:16 Director Deals - Hikma Pharmaceuticals PLC (HIK) 06 Sep 2019 | 15:30 Broker Forecast - Barclays Capital issues a broker note on Hikma Pharmaceuticals PLC 20 Aug 2019 | 08:40 Cocktail of risks sours FTSE 100 performance 09 Aug 2019 | 16:45 FTSE gathers some ground after GDP-inspired fall for the pound 09 Aug 2019 | 12:08 Broker Forecast - Peel Hunt issues a broker note on Hikma Pharmaceuticals PLC 09 Aug 2019 | 09:30 Hikma Pharmaceuticals acquires manufacturing platform, two pipeline products from Insys Therapeutics 09 Aug 2019 | 09:14 UK stocks open down 0.2% as Italian coalition government teeters 09 Aug 2019 | 09:02 Hikma Pharmaceuticals upgrades outlook amid 'strong' sales in H1 09 Aug 2019 | 07:19 Hikma Pharmaceuticals inks agreement to sell Gedeon Richter's antipsychotic in MENA region 25 Jul 2019 | 09:01 Hikma Pharmaceuticals enters into supply agreement with Civica 23 Jul 2019 | 13:09 Hikma Pharmaceuticals on track to meet expectations amid 'good' start to year 17 May 2019 | 07:44 Hikma Pharmaceuticals launches injectable antibiotic treatment in US 01 May 2019 | 13:28 Broker Forecast - Barclays Capital issues a broker note on Hikma Pharmaceuticals PLC 21 Mar 2019 | 10:00 Broker Forecast - Jefferies International issues a broker note on Hikma Pharmaceuticals PLC 19 Mar 2019 | 10:10 Broker Forecast - Citigroup issues a broker note on Hikma Pharmaceuticals PLC 19 Mar 2019 | 10:00 Director Deals - Hikma Pharmaceuticals PLC (HIK) 18 Mar 2019 | 15:45 Director Deals - Hikma Pharmaceuticals PLC (HIK) 18 Mar 2019 | 15:40 Director Deals - Hikma Pharmaceuticals PLC (HIK) 15 Mar 2019 | 11:35

Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Tangible Assets
870.0
828.0
Intangible Assets & Goodwill
766.0
785.0
Investments & Other Non-Current Assets
193.0
201.0
Total Non-Current Assets
1,829.0
1,814.0
Inventory
528.0
488.0
Trade & Receivables
731.0
707.0
Cash & Receivables
276.0
227.0
Other Current Assets & Assets Held for Resale
133.0
152.0
Total Assets
3,497.0
3,388.0

Liabilities (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Short Term Liabilities
893.0
797.0
Long Term Liabilities
907.0
1,063.0
Other Liabilities / Pension etc
0.0
0.0
Total Liabilities
1,800.0
1,860.0

Net Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Net Assets
1,697.0
1,528.0

Equity (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Share Capital
40.0
40.0
Minority Interests
12.0
14.0
Retained Earnings
1,580.0
0.0
Share Premium Account
282.0
282.0
Other Equity
-217.0
1,192.0
Total Equity
1,697.0
1,528.0

Cashflow (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Cashflow from Operating Activities
430.0
443.0
Cashflow Before Financing
334.0
292.0
Increase / Decrease in Cash
56.0
72.0

Income (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Turnover
2,070.0
1,936.0
Cost of Sales
1,020.0
969.0
Gross Profit
1,050.0
967.0
Operating Profit
371.0
-747.0
Pre-Tax Profit
293.0
-738.0
Profit / Loss for the Year
285.0
-839.0

Dividend History

Data has been provided by AJ Bell

Period
Ex-Dividend Date
Payment Date
H1 Dividend
22 Aug 2019
23 Sep 2019
H2 Dividend
04 Apr 2019
22 May 2019
H1 Dividend
23 Aug 2018
21 Sep 2018
H2 Dividend
05 Apr 2018
24 May 2018
H1 Dividend
24 Aug 2017
22 Sep 2017
H2 Dividend
06 Apr 2017
25 May 2017
H1 Dividend
01 Sep 2016
30 Sep 2016
H2 Dividend
07 Apr 2016
19 May 2016
H1 Dividend
27 Aug 2015
25 Sep 2015
H2 Dividend
16 Apr 2015
21 May 2015
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.